Device Trial Radar · NCT05978180
Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2)
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Oct 18, 2023
Primary completion
Nov 13, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- LabrhaNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Statitec
- First posted
- Aug 7, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies. The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly. The present clinical investigation has the objective to evaluate the safety and efficacy of use of Pandora, a hyaluronic acid associated with tranexamic acid, in a single injection (HO-1) or in three injections performed weekly (HS-3), compared to a referred and commercialized medical device.
Conditions
- Knee Osteoarthritis
Interventions
Medical Device : HO-1Device
The injection will be performed at Day 1.
Medical Device : HS-3Device
The three injections will be performed at Days 1, 8 and 15.
Medical Device : SINOVIAL® ONEDevice
The injection will be performed at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of the two medical devices containing Pandora gel, HO-1 and HS-3, on walking pain in the target knee, compared to the SINOVIAL® ONE.Time frame: 6 months
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
Cabinet de Rhumatologie
Annecy, France
Centre de Chirurgie Orthopédique du Beaujolais
Arnas, France
Centre de Médecine du Sport du Beaujolais
Arnas, France
32 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.